Sunshine Biopharma Inc (SBFM)

[hssbwwmp]

Who knows what type of PR will come out, but it will likely be related to progress on the SBFM topics below:

July 2022: expanded collaboration with the University of Arizona to accelerate the development of our novel PLpro inhibitors for our anti-Coronavirus treatment program.

October 2022: acquired Canadian generic pharmaceuticals company, Nora Pharma Inc., with sales of approximately $14 million. Sunshine Biopharma now has over 50 generic prescription drugs on the market in Canada with plans to grow further throughout North America and potentially other markets around the world.

November 2022: vigorously pushed forward with our oncology K1.1 mRNA development program by entering into a key collaboration arrangement with a leading lipid nano-particle (LNP) formulation company in North America. Beginning in March, 2023, our partner generated K1.1-LNP formulations will be used to conduct in vivo studies on xenograft mice expressing the in vitro tested human cancers as well as liver cancer. Should these mice studies prove successful, the Company can advance relatively rapidly to conducting human trials.

2023: objectives going forward will be focused on achieving profitability and investing in our proprietary drug development program.